Glibenclamide Tablet as an Oral Anti Diabetic

It is used for cases of Diabetes Mellitus type 2 if there are not responses by dietary program. Glibenclamide as an oral anti diabetic medications promotes the increased insulin secretion from the beta cell of islet tissue in the pancreas by means of an unspecific processed, decreases hepatic glycogenolysis and gluconeogenesis. Apparently increases insulin sensitivity of extra pancreatic tissues. Overall is a reduction in blood glucose concentration only, in those patients whose pancreas is capable of synthesizing insulin. As an oral anti diabetic medications apparently do not influence the production of insulin by beta cells but seem to enhance its release from these pancreatic cells. Some patent supplies of it by trade name like as: Daonil and semi daonil, Gluconic, Harmida, Renabetic, and others.

Glibenclamide is given on adult diabetic case or non insulin dependent diabetes mellitus.

Dosage and Administration:
Usual adult dose initially 2,5 mg – 5 mg oral tablet once a day, the dosage being adjusted in increments on more than 2,5 mg at weekly interval until diabetic control is obtained or until the total daily dose reaches 20 mg. usual adult prescribing limits up to 20 mg daily. Therapy in patient who may be more sensitive to Glibenclamide , such as elderly patient or patient with impaired renal or hepatic function, should be initiated at 1,25 mg once a day.

Warning and Precautions:
Avoiding alcoholic beverages and do not take other medicines unless prescribed or approved by the physician.

Side Effects:
Nausea, anxiety and confusion (hypoglycemia), hypersensitivity reaction involving the skin, leucopenia, and thrombocytopenia are as side effects of Glibenclamide.

Contra Indications:
Glibenclamide may not be administrated to the patients whose suffered insulin dependent diabetes mellitus (diabetes type 1), diabetic coma, diabetic metabolic decompensation, severe renal impairment, liver and adrenocortical, pregnant women and nursing mother, hypersensitive to glibenclamide.


Thanks for read our article for update information please subscriber our newslatter below